 Edith Zemanick
Concepts (234)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cystic Fibrosis | 81 | 2026 | 1171 | 14.600 |
Why?
| | Cystic Fibrosis Transmembrane Conductance Regulator | 24 | 2026 | 374 | 6.330 |
Why?
| | Sweat | 8 | 2026 | 52 | 3.400 |
Why?
| | Chlorides | 6 | 2026 | 138 | 3.180 |
Why?
| | Microbiota | 13 | 2024 | 736 | 2.940 |
Why?
| | Quinolones | 17 | 2026 | 206 | 2.780 |
Why?
| | Chloride Channel Agonists | 11 | 2026 | 111 | 2.740 |
Why?
| | Pseudomonas Infections | 12 | 2023 | 231 | 2.680 |
Why?
| | Aminophenols | 17 | 2026 | 204 | 2.510 |
Why?
| | Anti-Bacterial Agents | 24 | 2025 | 1940 | 2.420 |
Why?
| | Pseudomonas aeruginosa | 13 | 2023 | 397 | 2.380 |
Why?
| | Respiratory Tract Infections | 7 | 2026 | 399 | 2.320 |
Why?
| | Sputum | 10 | 2025 | 302 | 2.100 |
Why?
| | Benzodioxoles | 13 | 2026 | 162 | 2.020 |
Why?
| | Indoles | 10 | 2026 | 510 | 2.010 |
Why?
| | Specimen Handling | 4 | 2025 | 183 | 1.870 |
Why?
| | Respiratory System | 6 | 2021 | 150 | 1.340 |
Why?
| | Drug Combinations | 9 | 2026 | 399 | 1.290 |
Why?
| | Oropharynx | 3 | 2021 | 46 | 1.190 |
Why?
| | Pyrazoles | 8 | 2026 | 518 | 1.130 |
Why?
| | Metagenome | 4 | 2013 | 127 | 1.120 |
Why?
| | DNA, Bacterial | 6 | 2019 | 320 | 1.100 |
Why?
| | Lung | 9 | 2023 | 4141 | 0.950 |
Why?
| | Aminopyridines | 6 | 2026 | 129 | 0.870 |
Why?
| | Cough | 1 | 2025 | 124 | 0.850 |
Why?
| | Child | 41 | 2026 | 22980 | 0.840 |
Why?
| | Inflammation | 6 | 2017 | 2921 | 0.830 |
Why?
| | Bronchoalveolar Lavage Fluid | 7 | 2019 | 641 | 0.830 |
Why?
| | Anti-Infective Agents | 2 | 2023 | 234 | 0.780 |
Why?
| | Humans | 82 | 2026 | 147306 | 0.750 |
Why?
| | Aspergillosis, Allergic Bronchopulmonary | 1 | 2021 | 11 | 0.700 |
Why?
| | RNA, Ribosomal, 16S | 5 | 2023 | 512 | 0.650 |
Why?
| | Adolescent | 29 | 2026 | 22826 | 0.620 |
Why?
| | Microbial Sensitivity Tests | 3 | 2021 | 367 | 0.610 |
Why?
| | Pyridines | 7 | 2026 | 610 | 0.610 |
Why?
| | Drug Resistance, Bacterial | 2 | 2021 | 185 | 0.580 |
Why?
| | Bacteria | 8 | 2023 | 769 | 0.530 |
Why?
| | Male | 43 | 2026 | 73954 | 0.530 |
Why?
| | Female | 45 | 2026 | 80081 | 0.510 |
Why?
| | Genetic Therapy | 4 | 2023 | 317 | 0.500 |
Why?
| | beta-Lactams | 3 | 2023 | 32 | 0.490 |
Why?
| | Nasopharynx | 1 | 2016 | 73 | 0.460 |
Why?
| | Respiratory Function Tests | 5 | 2025 | 545 | 0.450 |
Why?
| | Meconium Ileus | 2 | 2026 | 12 | 0.450 |
Why?
| | Carrier State | 1 | 2016 | 79 | 0.440 |
Why?
| | Pyrrolidines | 6 | 2026 | 126 | 0.440 |
Why?
| | Lung Diseases | 3 | 2018 | 787 | 0.420 |
Why?
| | Bacteria, Anaerobic | 2 | 2011 | 25 | 0.410 |
Why?
| | Child, Preschool | 14 | 2025 | 12017 | 0.410 |
Why?
| | Vital Capacity | 1 | 2014 | 293 | 0.400 |
Why?
| | Respiratory Sounds | 1 | 2014 | 103 | 0.390 |
Why?
| | Mutation | 12 | 2023 | 4130 | 0.390 |
Why?
| | Genotype | 4 | 2026 | 1875 | 0.380 |
Why?
| | Saliva | 1 | 2015 | 252 | 0.380 |
Why?
| | Bronchiectasis | 1 | 2013 | 115 | 0.350 |
Why?
| | Precision Medicine | 1 | 2016 | 464 | 0.350 |
Why?
| | Age Factors | 2 | 2025 | 3372 | 0.340 |
Why?
| | Quinolines | 4 | 2026 | 192 | 0.330 |
Why?
| | Polymerase Chain Reaction | 2 | 2011 | 1046 | 0.330 |
Why?
| | Feasibility Studies | 2 | 2025 | 1147 | 0.320 |
Why?
| | Disease Management | 1 | 2014 | 654 | 0.300 |
Why?
| | Disease Progression | 6 | 2025 | 2892 | 0.300 |
Why?
| | Cytokines | 2 | 2015 | 2087 | 0.300 |
Why?
| | Young Adult | 14 | 2026 | 14437 | 0.300 |
Why?
| | Adult | 18 | 2026 | 41406 | 0.290 |
Why?
| | Cardiovascular Diseases | 1 | 2021 | 2218 | 0.280 |
Why?
| | Pneumonia, Bacterial | 1 | 2009 | 115 | 0.280 |
Why?
| | Case-Control Studies | 5 | 2025 | 3660 | 0.260 |
Why?
| | Infant | 7 | 2023 | 10195 | 0.250 |
Why?
| | Biofilms | 2 | 2020 | 292 | 0.250 |
Why?
| | Clinical Trials as Topic | 3 | 2024 | 1072 | 0.240 |
Why?
| | Thiazolidines | 1 | 2026 | 13 | 0.240 |
Why?
| | Quinuclidines | 1 | 2026 | 11 | 0.240 |
Why?
| | Diabetes Mellitus | 2 | 2025 | 1107 | 0.240 |
Why?
| | Treatment Outcome | 10 | 2026 | 11947 | 0.240 |
Why?
| | Oxygen | 2 | 2020 | 998 | 0.210 |
Why?
| | Prospective Studies | 7 | 2023 | 8166 | 0.210 |
Why?
| | Monitoring, Physiologic | 1 | 2025 | 290 | 0.200 |
Why?
| | Endpoint Determination | 1 | 2024 | 85 | 0.200 |
Why?
| | Olfaction Disorders | 1 | 2023 | 74 | 0.190 |
Why?
| | Fetal Diseases | 1 | 2024 | 194 | 0.190 |
Why?
| | Central Venous Catheters | 1 | 2023 | 53 | 0.180 |
Why?
| | C-Reactive Protein | 1 | 2025 | 430 | 0.180 |
Why?
| | Respiratory Syncytial Virus Infections | 1 | 2024 | 140 | 0.180 |
Why?
| | Advisory Committees | 1 | 2024 | 233 | 0.180 |
Why?
| | Methicillin-Resistant Staphylococcus aureus | 2 | 2016 | 251 | 0.180 |
Why?
| | Catheter-Related Infections | 1 | 2023 | 98 | 0.180 |
Why?
| | Aspergillus fumigatus | 1 | 2021 | 26 | 0.170 |
Why?
| | Catheterization, Peripheral | 1 | 2023 | 120 | 0.170 |
Why?
| | Antimicrobial Cationic Peptides | 2 | 2019 | 81 | 0.170 |
Why?
| | Staphylococcal Infections | 2 | 2016 | 395 | 0.170 |
Why?
| | Catheterization, Central Venous | 1 | 2023 | 124 | 0.170 |
Why?
| | Trachea | 1 | 2023 | 258 | 0.170 |
Why?
| | Tobramycin | 3 | 2023 | 63 | 0.160 |
Why?
| | Quality Improvement | 3 | 2019 | 1321 | 0.160 |
Why?
| | Venous Thrombosis | 1 | 2023 | 199 | 0.160 |
Why?
| | Quality of Life | 3 | 2023 | 3246 | 0.160 |
Why?
| | Pseudomonas | 2 | 2022 | 30 | 0.150 |
Why?
| | Respiratory System Agents | 1 | 2020 | 22 | 0.150 |
Why?
| | Luminescent Measurements | 1 | 2019 | 75 | 0.150 |
Why?
| | Bacteriological Techniques | 1 | 2019 | 66 | 0.150 |
Why?
| | International Cooperation | 1 | 2019 | 198 | 0.140 |
Why?
| | Genetic Variation | 2 | 2021 | 995 | 0.140 |
Why?
| | United States | 6 | 2025 | 16313 | 0.140 |
Why?
| | Bacterial Infections | 1 | 2020 | 247 | 0.140 |
Why?
| | Bronchopulmonary Dysplasia | 1 | 2024 | 437 | 0.140 |
Why?
| | Drug Prescriptions | 1 | 2020 | 293 | 0.140 |
Why?
| | Critical Pathways | 1 | 2019 | 111 | 0.140 |
Why?
| | Alleles | 1 | 2021 | 909 | 0.130 |
Why?
| | Immunoglobulin A | 1 | 2019 | 214 | 0.130 |
Why?
| | Aptamers, Nucleotide | 1 | 2019 | 88 | 0.130 |
Why?
| | Nontuberculous Mycobacteria | 1 | 2019 | 189 | 0.130 |
Why?
| | Delphi Technique | 1 | 2019 | 347 | 0.130 |
Why?
| | Gas Chromatography-Mass Spectrometry | 1 | 2018 | 125 | 0.130 |
Why?
| | Volatile Organic Compounds | 1 | 2018 | 48 | 0.130 |
Why?
| | Consensus | 1 | 2019 | 476 | 0.130 |
Why?
| | Infant, Newborn | 4 | 2024 | 6543 | 0.130 |
Why?
| | Safety | 1 | 2019 | 358 | 0.130 |
Why?
| | Blood Proteins | 1 | 2019 | 239 | 0.130 |
Why?
| | Membrane Transport Modulators | 1 | 2017 | 7 | 0.130 |
Why?
| | Aldehyde Oxidoreductases | 1 | 2017 | 28 | 0.130 |
Why?
| | Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2016 | 43 | 0.120 |
Why?
| | Rifampin | 1 | 2017 | 79 | 0.120 |
Why?
| | Azithromycin | 2 | 2023 | 101 | 0.120 |
Why?
| | Respiratory Mucosa | 1 | 2019 | 324 | 0.120 |
Why?
| | Pilot Projects | 2 | 2023 | 1912 | 0.120 |
Why?
| | Foundations | 1 | 2016 | 27 | 0.120 |
Why?
| | Cholesterol Esters | 1 | 2015 | 7 | 0.110 |
Why?
| | Cohort Studies | 2 | 2017 | 6099 | 0.110 |
Why?
| | Pulmonary Medicine | 1 | 2016 | 78 | 0.110 |
Why?
| | Regression Analysis | 1 | 2017 | 1003 | 0.110 |
Why?
| | Patient Selection | 1 | 2019 | 746 | 0.110 |
Why?
| | Radiography | 1 | 2017 | 862 | 0.110 |
Why?
| | Staphylococcus aureus | 2 | 2018 | 459 | 0.110 |
Why?
| | Mycobacterium Infections, Nontuberculous | 1 | 2019 | 339 | 0.110 |
Why?
| | Longitudinal Studies | 3 | 2021 | 3029 | 0.110 |
Why?
| | Bronchi | 1 | 2016 | 263 | 0.110 |
Why?
| | Retrospective Studies | 5 | 2025 | 17561 | 0.110 |
Why?
| | Immunoglobulin G | 1 | 2019 | 901 | 0.110 |
Why?
| | Enterobacteriaceae | 1 | 2015 | 44 | 0.110 |
Why?
| | Staphylococcus | 1 | 2015 | 74 | 0.110 |
Why?
| | Enterobacteriaceae Infections | 1 | 2015 | 43 | 0.110 |
Why?
| | Double-Blind Method | 1 | 2019 | 2080 | 0.110 |
Why?
| | Stenotrophomonas maltophilia | 1 | 2014 | 1 | 0.100 |
Why?
| | Achromobacter denitrificans | 1 | 2014 | 1 | 0.100 |
Why?
| | Forced Expiratory Volume | 3 | 2020 | 451 | 0.100 |
Why?
| | Spirometry | 1 | 2015 | 235 | 0.100 |
Why?
| | Administration, Oral | 3 | 2023 | 874 | 0.100 |
Why?
| | Genotyping Techniques | 1 | 2014 | 72 | 0.100 |
Why?
| | Multivariate Analysis | 1 | 2017 | 1550 | 0.100 |
Why?
| | Chronic Disease | 1 | 2019 | 1845 | 0.100 |
Why?
| | Genetic Markers | 1 | 2014 | 338 | 0.100 |
Why?
| | Biomarkers | 5 | 2020 | 4354 | 0.090 |
Why?
| | DNA Mutational Analysis | 1 | 2014 | 414 | 0.090 |
Why?
| | Blood Glucose | 2 | 2025 | 2359 | 0.090 |
Why?
| | Leukocyte Elastase | 1 | 2012 | 75 | 0.090 |
Why?
| | Middle Aged | 5 | 2025 | 36821 | 0.090 |
Why?
| | Administration, Inhalation | 2 | 2023 | 572 | 0.090 |
Why?
| | Asthma | 1 | 2024 | 1805 | 0.090 |
Why?
| | Sequence Analysis, DNA | 1 | 2015 | 780 | 0.090 |
Why?
| | Proteolysis | 1 | 2012 | 173 | 0.090 |
Why?
| | Proteomics | 1 | 2019 | 1205 | 0.090 |
Why?
| | Feces | 1 | 2015 | 500 | 0.090 |
Why?
| | DNA Barcoding, Taxonomic | 1 | 2011 | 16 | 0.080 |
Why?
| | Animals | 4 | 2019 | 38417 | 0.080 |
Why?
| | Biota | 1 | 2011 | 29 | 0.080 |
Why?
| | Phenotype | 1 | 2019 | 3216 | 0.080 |
Why?
| | Neonatal Screening | 1 | 2012 | 185 | 0.080 |
Why?
| | Intestinal Mucosa | 1 | 2015 | 676 | 0.070 |
Why?
| | Risk Assessment | 1 | 2019 | 3784 | 0.070 |
Why?
| | Morbidity | 1 | 2009 | 323 | 0.070 |
Why?
| | Practice Guidelines as Topic | 1 | 2016 | 1598 | 0.070 |
Why?
| | Pediatrics | 1 | 2016 | 1139 | 0.060 |
Why?
| | Gastrointestinal Microbiome | 1 | 2015 | 773 | 0.060 |
Why?
| | Cross-Sectional Studies | 2 | 2021 | 6011 | 0.060 |
Why?
| | Cytochrome P-450 CYP3A | 1 | 2026 | 93 | 0.060 |
Why?
| | Follow-Up Studies | 1 | 2014 | 5478 | 0.050 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2020 | 2030 | 0.050 |
Why?
| | Catheters, Indwelling | 1 | 2023 | 96 | 0.050 |
Why?
| | Reproducibility of Results | 1 | 2010 | 3448 | 0.050 |
Why?
| | Pregnancy | 2 | 2026 | 7276 | 0.040 |
Why?
| | Anaerobiosis | 1 | 2021 | 65 | 0.040 |
Why?
| | Styrenes | 1 | 2020 | 3 | 0.040 |
Why?
| | Aged | 1 | 2021 | 26516 | 0.040 |
Why?
| | Porphyrins | 1 | 2020 | 16 | 0.040 |
Why?
| | Colistin | 1 | 2020 | 10 | 0.040 |
Why?
| | Fluorobenzenes | 1 | 2020 | 17 | 0.040 |
Why?
| | Pyridinium Compounds | 1 | 2020 | 31 | 0.040 |
Why?
| | Dysbiosis | 1 | 2021 | 188 | 0.040 |
Why?
| | Serologic Tests | 1 | 2019 | 54 | 0.040 |
Why?
| | Diagnostic Tests, Routine | 1 | 2019 | 107 | 0.030 |
Why?
| | Fluorocarbons | 1 | 2020 | 122 | 0.030 |
Why?
| | Medical History Taking | 1 | 2019 | 119 | 0.030 |
Why?
| | Immunity, Humoral | 1 | 2019 | 119 | 0.030 |
Why?
| | Incidence | 1 | 2025 | 2954 | 0.030 |
Why?
| | Homozygote | 1 | 2018 | 199 | 0.030 |
Why?
| | Prevalence | 1 | 2025 | 2889 | 0.030 |
Why?
| | Symptom Assessment | 1 | 2019 | 137 | 0.030 |
Why?
| | Cytochrome P-450 CYP3A Inducers | 1 | 2017 | 5 | 0.030 |
Why?
| | Glucose Tolerance Test | 1 | 2018 | 361 | 0.030 |
Why?
| | Area Under Curve | 1 | 2018 | 334 | 0.030 |
Why?
| | Minocycline | 1 | 2016 | 23 | 0.030 |
Why?
| | Chlorhexidine | 1 | 2016 | 24 | 0.030 |
Why?
| | Biological Availability | 1 | 2017 | 146 | 0.030 |
Why?
| | Biphenyl Compounds | 1 | 2017 | 67 | 0.030 |
Why?
| | Severity of Illness Index | 1 | 2025 | 2974 | 0.030 |
Why?
| | Anti-Infective Agents, Local | 1 | 2016 | 41 | 0.030 |
Why?
| | Registries | 1 | 2025 | 2434 | 0.030 |
Why?
| | ROC Curve | 1 | 2018 | 626 | 0.030 |
Why?
| | Drug Interactions | 1 | 2017 | 405 | 0.030 |
Why?
| | Pharmacogenetics | 1 | 2017 | 176 | 0.030 |
Why?
| | Capsule Endoscopes | 1 | 2015 | 7 | 0.030 |
Why?
| | Hypoglycemic Agents | 1 | 2025 | 1415 | 0.030 |
Why?
| | Leukocyte L1 Antigen Complex | 1 | 2015 | 41 | 0.030 |
Why?
| | Permeability | 1 | 2015 | 170 | 0.030 |
Why?
| | Telemedicine | 1 | 2024 | 978 | 0.030 |
Why?
| | Nanoparticles | 1 | 2020 | 524 | 0.020 |
Why?
| | Drug Monitoring | 1 | 2017 | 402 | 0.020 |
Why?
| | Autoimmunity | 1 | 2019 | 935 | 0.020 |
Why?
| | Liver Cirrhosis | 1 | 2015 | 289 | 0.020 |
Why?
| | Blotting, Western | 1 | 2015 | 1186 | 0.020 |
Why?
| | Genetic Carrier Screening | 1 | 2012 | 32 | 0.020 |
Why?
| | Trypsinogen | 1 | 2012 | 11 | 0.020 |
Why?
| | False Positive Reactions | 1 | 2012 | 124 | 0.020 |
Why?
| | Decision Making | 1 | 2019 | 994 | 0.020 |
Why?
| | DNA | 1 | 2018 | 1444 | 0.020 |
Why?
| | Surveys and Questionnaires | 1 | 2023 | 6164 | 0.020 |
Why?
| | Prognosis | 1 | 2018 | 4384 | 0.020 |
Why?
| | Bacterial Proteins | 1 | 2016 | 977 | 0.020 |
Why?
| | Proteins | 1 | 2015 | 1024 | 0.020 |
Why?
| | Genes, rRNA | 1 | 2007 | 38 | 0.020 |
Why?
| | Genes, Bacterial | 1 | 2007 | 152 | 0.020 |
Why?
| | Risk Factors | 1 | 2019 | 11017 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 2007 | 2886 | 0.010 |
Why?
|
|
Zemanick's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|